HRP20180640T1 - Anti-b7-h3 antitijelo - Google Patents
Anti-b7-h3 antitijeloInfo
- Publication number
- HRP20180640T1 HRP20180640T1 HRP20180640TT HRP20180640T HRP20180640T1 HR P20180640 T1 HRP20180640 T1 HR P20180640T1 HR P20180640T T HRP20180640T T HR P20180640TT HR P20180640 T HRP20180640 T HR P20180640T HR P20180640 T1 HRP20180640 T1 HR P20180640T1
- Authority
- HR
- Croatia
- Prior art keywords
- antibody
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161478878P | 2011-04-25 | 2011-04-25 | |
JP2011097645 | 2011-04-25 | ||
PCT/JP2012/060904 WO2012147713A1 (ja) | 2011-04-25 | 2012-04-24 | 抗b7-h3抗体 |
EP12776528.7A EP2703486B1 (en) | 2011-04-25 | 2012-04-24 | Anti-b7-h3 antibody |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20180640T1 true HRP20180640T1 (hr) | 2018-06-01 |
Family
ID=47072232
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20180640TT HRP20180640T1 (hr) | 2011-04-25 | 2018-04-23 | Anti-b7-h3 antitijelo |
Country Status (26)
Country | Link |
---|---|
US (2) | US9371395B2 (hr) |
EP (1) | EP2703486B1 (hr) |
JP (2) | JP5917498B2 (hr) |
KR (1) | KR102030987B1 (hr) |
CN (1) | CN103687945B (hr) |
AU (1) | AU2012248470B2 (hr) |
CA (1) | CA2834136C (hr) |
CO (1) | CO6811812A2 (hr) |
DK (1) | DK2703486T3 (hr) |
ES (1) | ES2667568T3 (hr) |
HR (1) | HRP20180640T1 (hr) |
HU (1) | HUE038685T2 (hr) |
IL (1) | IL229061B (hr) |
LT (1) | LT2703486T (hr) |
MX (1) | MX344773B (hr) |
MY (1) | MY173377A (hr) |
PL (1) | PL2703486T3 (hr) |
PT (1) | PT2703486T (hr) |
RS (1) | RS57279B1 (hr) |
RU (1) | RU2668170C2 (hr) |
SG (1) | SG194620A1 (hr) |
SI (1) | SI2703486T1 (hr) |
TR (1) | TR201808018T4 (hr) |
TW (1) | TWI561531B (hr) |
WO (1) | WO2012147713A1 (hr) |
ZA (1) | ZA201307983B (hr) |
Families Citing this family (74)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL2703486T3 (pl) * | 2011-04-25 | 2018-07-31 | Daiichi Sankyo Company, Limited | Przeciwciało anty-b7-h3 |
WO2014160627A1 (en) | 2013-03-25 | 2014-10-02 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-cd276 polypeptides, proteins, and chimeric antigen receptors |
EP3149040A1 (en) * | 2014-05-29 | 2017-04-05 | Spring Bioscience Corporation | Anti-b7-h3 antibodies and diagnostic uses thereof |
JP6613304B2 (ja) | 2014-09-17 | 2019-12-04 | ザ ユナイテッド ステイツ オブ アメリカ, アズ リプレゼンテッド バイ ザ セクレタリー, デパートメント オブ ヘルス アンド ヒューマン サービシーズ | 抗cd276抗体(b7h3) |
CA3138083A1 (en) * | 2014-12-22 | 2016-06-30 | Systimmune, Inc. | Bispecific tetravalent antibodies and methods of making and using thereof |
KR20180021723A (ko) | 2015-06-29 | 2018-03-05 | 다이이찌 산쿄 가부시키가이샤 | 항체-약물 콘주게이트의 선택적 제조 방법 |
TWI751979B (zh) * | 2015-09-24 | 2022-01-11 | 日商第一三共股份有限公司 | 抗garp抗體 |
WO2017062619A2 (en) | 2015-10-08 | 2017-04-13 | Macrogenics, Inc. | Combination therapy for the treatment of cancer |
WO2017106061A1 (en) | 2015-12-14 | 2017-06-22 | Macrogenics, Inc. | Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof |
SG10201601719RA (en) | 2016-03-04 | 2017-10-30 | Agency Science Tech & Res | Anti-LAG-3 Antibodies |
MX2018012433A (es) | 2016-04-15 | 2019-03-01 | Macrogenics Inc | Moleculas de union b7-h3 novedosas, conjugados anticuerpo-farmaco de los mismos y metodos de uso de los mismos. |
SG10201603721TA (en) | 2016-05-10 | 2017-12-28 | Agency Science Tech & Res | Anti-CTLA-4 Antibodies |
SG10201913326UA (en) | 2016-06-07 | 2020-02-27 | Macrogenics Inc | Combination therapy |
WO2017214339A1 (en) * | 2016-06-08 | 2017-12-14 | Abbvie Inc. | Anti-b7-h3 antibodies and antibody drug conjugates |
WO2017214322A1 (en) * | 2016-06-08 | 2017-12-14 | Abbvie Inc. | Anti-b7-h3 antibodies and antibody drug conjugates |
CN116284404A (zh) * | 2016-06-08 | 2023-06-23 | 艾伯维公司 | 抗b7-h3抗体和抗体药物偶联物 |
CN107840892A (zh) * | 2016-09-20 | 2018-03-27 | 上海药明生物技术有限公司 | 新型抗‑pcsk9抗体 |
KR102585848B1 (ko) | 2017-02-24 | 2023-10-11 | 마크로제닉스, 인크. | Cd137 및 종양 항원에 결합할 수 있는 이중특이적 결합 분자, 및 그것의 용도 |
WO2018156180A1 (en) | 2017-02-24 | 2018-08-30 | Kindred Biosciences, Inc. | Anti-il31 antibodies for veterinary use |
CN109843927B (zh) * | 2017-03-06 | 2022-06-21 | 江苏恒瑞医药股份有限公司 | 抗b7-h3抗体、其抗原结合片段及其医药用途 |
JP7158403B2 (ja) | 2017-03-31 | 2022-10-21 | ジエンス ヘンルイ メデイシンカンパニー リミテッド | B7-h3抗体、その抗原結合フラグメント、及びそれらの医学的使用 |
TW201909926A (zh) * | 2017-08-04 | 2019-03-16 | 大陸商江蘇恆瑞醫藥股份有限公司 | B7h3抗體-藥物偶聯物及其醫藥用途 |
BR112020003533A2 (pt) | 2017-08-25 | 2020-11-17 | Five Prime Therapeutics, Inc. | anticorpos b7-h4 e métodos de uso dos mesmos |
SG11202005557TA (en) | 2017-12-12 | 2020-07-29 | Macrogenics Inc | Bispecific cd 16-binding molecules and their use in the treatment of disease |
CN110090306B (zh) * | 2018-01-31 | 2023-04-07 | 江苏恒瑞医药股份有限公司 | 双醛连接臂的配体-药物偶联物、其制备方法及其应用 |
US11685781B2 (en) | 2018-02-15 | 2023-06-27 | Macrogenics, Inc. | Variant CD3-binding domains and their use in combination therapies for the treatment of disease |
CN111971308A (zh) | 2018-03-02 | 2020-11-20 | 戊瑞治疗有限公司 | B7-h4抗体及其使用方法 |
WO2019225787A1 (ko) * | 2018-05-24 | 2019-11-28 | 에이비엘바이오 주식회사 | 항-b7-h3 항체 및 그 용도 |
CA3103629A1 (en) | 2018-06-15 | 2019-12-19 | Flagship Pioneering Innovations V, Inc. | Increasing immune activity through modulation of postcellular signaling factors |
AU2019302152A1 (en) * | 2018-07-10 | 2021-01-07 | Daiichi Sankyo Company, Limited | Anti-sirpalpha antibody |
WO2020018964A1 (en) | 2018-07-20 | 2020-01-23 | Fred Hutchinson Cancer Research Center | Compositions and methods for controlled expression of antigen-specific receptors |
CN112789291A (zh) * | 2018-08-08 | 2021-05-11 | 蜻蜓疗法股份有限公司 | 结合nkg2d、cd16和肿瘤相关抗原的蛋白质 |
WO2020047299A1 (en) | 2018-08-30 | 2020-03-05 | HCW Biologics, Inc. | Multi-chain chimeric polypeptides and uses thereof |
US11401324B2 (en) | 2018-08-30 | 2022-08-02 | HCW Biologics, Inc. | Single-chain chimeric polypeptides and uses thereof |
JP7449292B2 (ja) | 2018-08-30 | 2024-03-13 | エイチシーダブリュー バイオロジックス インコーポレイテッド | 加齢関連障害の治療法 |
CN110950953B (zh) * | 2018-09-26 | 2022-05-13 | 福州拓新天成生物科技有限公司 | 抗b7-h3的单克隆抗体及其在细胞治疗中的应用 |
CA3114474A1 (en) | 2018-09-30 | 2020-04-02 | Jiangsu Hengrui Medicine Co., Ltd. | Anti-b7h3 antibody-exatecan analog conjugate and medicinal use thereof |
CN112239502A (zh) * | 2019-07-18 | 2021-01-19 | 上海复旦张江生物医药股份有限公司 | 一种抗b7-h3抗体及其制备方法、其偶联物和应用 |
CN110305213B (zh) * | 2018-11-09 | 2023-03-10 | 泰州复旦张江药业有限公司 | 一种抗b7-h3抗体及其制备方法、其偶联物和应用 |
WO2020140094A1 (en) * | 2018-12-27 | 2020-07-02 | Gigagen, Inc. | Anti-b7-h3 binding proteins and methods of use thereof |
CN109851673B (zh) * | 2019-01-22 | 2023-07-25 | 苏州旭光科星抗体生物科技有限公司 | 一种抗人b7-h3单克隆抗体的制备方法及其免疫组化检测方法及其应用及其试剂盒 |
WO2020227159A2 (en) | 2019-05-03 | 2020-11-12 | Flagship Pioneering Innovations V, Inc. | Methods of modulating immune activity |
EP3987010A1 (en) | 2019-06-21 | 2022-04-27 | HCW Biologics, Inc. | Multi-chain chimeric polypeptides and uses thereof |
AU2020299305A1 (en) * | 2019-07-03 | 2022-01-06 | Crystal Bioscience Inc. | Anti-B7-H3 antibody and methods of use thereof |
KR20210006637A (ko) * | 2019-07-09 | 2021-01-19 | 주식회사 와이바이오로직스 | B7-h3(cd276)에 특이적으로 결합하는 항체 및 그의 용도 |
WO2021038975A1 (ja) | 2019-08-28 | 2021-03-04 | 株式会社アネロファーマ・サイエンス | ダイアボディ型BsAbを発現・分泌するビフィドバクテリウム属細菌 |
WO2021052307A1 (zh) * | 2019-09-16 | 2021-03-25 | 南京圣和药业股份有限公司 | 一种抗b7-h3抗体及其应用 |
CN110642948B (zh) * | 2019-10-09 | 2021-06-29 | 达石药业(广东)有限公司 | B7-h3纳米抗体、其制备方法及用途 |
EP3822288A1 (en) * | 2019-11-18 | 2021-05-19 | Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts | Antibodies targeting, and other modulators of, the cd276 antigen, and uses thereof |
WO2021097800A1 (en) * | 2019-11-22 | 2021-05-27 | Abl Bio Inc. | Anti-pd-l1/anti-b7-h3 multispecific antibodies and uses thereof |
WO2021127217A1 (en) | 2019-12-17 | 2021-06-24 | Flagship Pioneering Innovations V, Inc. | Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly |
KR20220140535A (ko) | 2020-02-11 | 2022-10-18 | 에이치씨더블유 바이올로직스, 인크. | 크로마토그래피 수지 및 이의 용도 |
AU2021220196A1 (en) | 2020-02-11 | 2022-08-04 | HCW Biologics, Inc. | Methods of activating regulatory T cells |
CA3169231A1 (en) | 2020-02-11 | 2021-08-19 | HCW Biologics, Inc. | Methods of treating age-related and inflammatory diseases |
CN113527487A (zh) * | 2020-04-22 | 2021-10-22 | 复星凯特生物科技有限公司 | 抗人b7-h3的单克隆抗体及其应用 |
CN115836087A (zh) | 2020-04-29 | 2023-03-21 | Hcw生物科技公司 | 抗cd26蛋白及其用途 |
KR20230031280A (ko) | 2020-06-01 | 2023-03-07 | 에이치씨더블유 바이올로직스, 인크. | 노화 관련 장애의 치료 방법 |
WO2021247003A1 (en) | 2020-06-01 | 2021-12-09 | HCW Biologics, Inc. | Methods of treating aging-related disorders |
CN113754766A (zh) * | 2020-06-02 | 2021-12-07 | 明慧医药(上海)有限公司 | 抗b7-h3抗体及其制备和应用 |
JP2023532339A (ja) | 2020-06-29 | 2023-07-27 | フラグシップ パイオニアリング イノベーションズ ブイ,インコーポレーテッド | サノトランスミッションを促進するためにエンジニアリングされたウイルス及び癌の処置におけるそれらの使用 |
CN112851812B (zh) * | 2020-06-30 | 2021-09-14 | 广州百暨基因科技有限公司 | 抗b7h3抗体及其应用 |
CA3198996A1 (en) | 2020-11-24 | 2022-06-02 | Matthew T. Burger | Bcl-xl inhibitor antibody-drug conjugates and methods of use thereof |
EP4269435A1 (en) * | 2020-12-23 | 2023-11-01 | Innovent Biologics (Singapore) Pte. Ltd. | Anti-b7-h3 antibody and uses thereof |
KR20230145038A (ko) | 2021-02-09 | 2023-10-17 | 메디링크 테라퓨틱스 (쑤저우) 컴퍼니, 리미티드 | 생물활성 물질 접합체, 이의 제조방법 및 이의 용도 |
EP4313109A1 (en) | 2021-03-31 | 2024-02-07 | Flagship Pioneering Innovations V, Inc. | Thanotransmission polypeptides and their use in treating cancer |
CA3224374A1 (en) | 2021-06-29 | 2023-01-05 | Flagship Pioneering Innovations V, Inc. | Immune cells engineered to promote thanotransmission and uses thereof |
CA3225932A1 (en) | 2021-07-19 | 2023-01-26 | Regeneron Pharmaceuticals, Inc. | Combination of checkpoint inhibitors and an oncolytic virus for treating cancer |
CN114380910B (zh) * | 2022-01-07 | 2023-04-28 | 苏州旭光科星抗体生物科技有限公司 | 靶向人b7-h3分子的人源化单克隆抗体及其应用 |
WO2023159102A1 (en) | 2022-02-17 | 2023-08-24 | Regeneron Pharmaceuticals, Inc. | Combinations of checkpoint inhibitors and oncolytic virus for treating cancer |
WO2023168363A1 (en) | 2022-03-02 | 2023-09-07 | HCW Biologics, Inc. | Method of treating pancreatic cancer |
WO2023221975A1 (zh) * | 2022-05-18 | 2023-11-23 | 苏州宜联生物医药有限公司 | 包含蛋白降解剂类生物活性化合物的抗体药物偶联物及其制备方法和用途 |
WO2023223097A1 (en) | 2022-05-20 | 2023-11-23 | Novartis Ag | Antibody drug conjugates |
WO2023225359A1 (en) | 2022-05-20 | 2023-11-23 | Novartis Ag | Antibody-drug conjugates of antineoplastic compounds and methods of use thereof |
WO2024077191A1 (en) | 2022-10-05 | 2024-04-11 | Flagship Pioneering Innovations V, Inc. | Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
EP0585287B1 (en) | 1990-07-10 | 1999-10-13 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
WO1993006213A1 (en) | 1991-09-23 | 1993-04-01 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
PT1024191E (pt) | 1991-12-02 | 2008-12-22 | Medical Res Council | Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos |
EP0656941B1 (en) | 1992-03-24 | 2005-06-01 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
GB9313509D0 (en) | 1993-06-30 | 1993-08-11 | Medical Res Council | Chemisynthetic libraries |
AU690171B2 (en) | 1993-12-03 | 1998-04-23 | Medical Research Council | Recombinant binding proteins and peptides |
DK2180007T4 (da) * | 1998-04-20 | 2017-11-27 | Roche Glycart Ag | Glycosyleringsteknik for antistoffer til forbedring af antistofafhængig cellecytotoxicitet |
EP2275540B1 (en) | 1999-04-09 | 2016-03-23 | Kyowa Hakko Kirin Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
US6891030B2 (en) * | 2000-07-27 | 2005-05-10 | Mayo Foundation For Medical Education And Research | T-cell immunoregulatory molecule |
MXPA03002974A (es) | 2000-10-06 | 2004-05-05 | Kyowa Hakko Kogyo Kk | Celulas que producen composiciones de anticuerpo. |
US7229960B2 (en) * | 2000-11-03 | 2007-06-12 | University Of Vermont And State Agricultural College | Methods and compositions for inhibiting GRB7 |
AU2002360307B2 (en) | 2001-11-01 | 2008-01-17 | The Uab Research Foundation | Combinations of DR5 antibody and other therapeutic agents |
DE602004002275T2 (de) | 2003-01-07 | 2007-09-06 | Symphogen A/S | Verfahren zur herstellung rekombinanterpolyklonaler proteine |
US20050002935A1 (en) * | 2003-04-17 | 2005-01-06 | Vincent Ling | Use of B7-H3 as an immunoregulatory agent |
ES2534288T3 (es) * | 2004-08-03 | 2015-04-21 | Innate Pharma | Composiciones terapéuticas contra el cáncer que seleccionan como objetivo 4Ig-B7-H3 |
US7592429B2 (en) | 2005-05-03 | 2009-09-22 | Ucb Sa | Sclerostin-binding antibody |
CN101104639A (zh) * | 2006-07-10 | 2008-01-16 | 苏州大学 | 抗人b7-h3单克隆抗体的制备及其应用 |
US7718774B2 (en) | 2006-11-08 | 2010-05-18 | Macrogenics, Inc. | TES7 and antibodies that bind thereto |
WO2008116219A2 (en) * | 2007-03-22 | 2008-09-25 | Sloan-Kettering Institute For Cancer Research | Uses of monoclonal antibody 8h9 |
PL2703486T3 (pl) * | 2011-04-25 | 2018-07-31 | Daiichi Sankyo Company, Limited | Przeciwciało anty-b7-h3 |
-
2012
- 2012-04-24 PL PL12776528T patent/PL2703486T3/pl unknown
- 2012-04-24 HU HUE12776528A patent/HUE038685T2/hu unknown
- 2012-04-24 WO PCT/JP2012/060904 patent/WO2012147713A1/ja active Application Filing
- 2012-04-24 SG SG2013079199A patent/SG194620A1/en unknown
- 2012-04-24 RU RU2013152164A patent/RU2668170C2/ru active
- 2012-04-24 JP JP2013512363A patent/JP5917498B2/ja active Active
- 2012-04-24 MX MX2013012285A patent/MX344773B/es active IP Right Grant
- 2012-04-24 MY MYPI2013003891A patent/MY173377A/en unknown
- 2012-04-24 DK DK12776528.7T patent/DK2703486T3/en active
- 2012-04-24 LT LTEP12776528.7T patent/LT2703486T/lt unknown
- 2012-04-24 US US13/455,021 patent/US9371395B2/en active Active
- 2012-04-24 TW TW101114495A patent/TWI561531B/zh active
- 2012-04-24 ES ES12776528.7T patent/ES2667568T3/es active Active
- 2012-04-24 KR KR1020137027860A patent/KR102030987B1/ko active Application Filing
- 2012-04-24 SI SI201231272T patent/SI2703486T1/en unknown
- 2012-04-24 RS RS20180646A patent/RS57279B1/sr unknown
- 2012-04-24 TR TR2018/08018T patent/TR201808018T4/tr unknown
- 2012-04-24 EP EP12776528.7A patent/EP2703486B1/en active Active
- 2012-04-24 CA CA2834136A patent/CA2834136C/en active Active
- 2012-04-24 AU AU2012248470A patent/AU2012248470B2/en active Active
- 2012-04-24 CN CN201280030835.0A patent/CN103687945B/zh active Active
- 2012-04-24 PT PT127765287T patent/PT2703486T/pt unknown
-
2013
- 2013-10-18 ZA ZA2013/07983A patent/ZA201307983B/en unknown
- 2013-10-24 IL IL229061A patent/IL229061B/en active IP Right Grant
- 2013-11-22 CO CO13275282A patent/CO6811812A2/es active IP Right Grant
-
2016
- 2016-04-06 JP JP2016076911A patent/JP6224759B2/ja active Active
- 2016-06-20 US US15/187,209 patent/US20160368990A1/en not_active Abandoned
-
2018
- 2018-04-23 HR HRP20180640TT patent/HRP20180640T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUS2300021I1 (hu) | Anti-IL-36R antitestek | |
HRP20180640T1 (hr) | Anti-b7-h3 antitijelo | |
IL259826A (en) | Anti-alphabetatisiar antibody | |
GB201103955D0 (en) | Antibodies | |
GB201112056D0 (en) | Antibodies | |
ZA201307642B (en) | Immunoassay | |
EP2930240A4 (en) | ANTI-FOLR1 ANTIBODY | |
ZA201407316B (en) | Anti-fgfr2 antibody | |
EP2826790A4 (en) | GREMLIN-1 ANTIBODY | |
ZA201407079B (en) | Cdr-modified anti-siglec-15 antibody | |
TWI563004B (en) | Anti-hxcr1 antibody | |
GB201112395D0 (en) | Immunoassay | |
GB201220242D0 (en) | Antibody | |
EP2848633A4 (en) | ANTI-CXADR ANTIBODY | |
EP2769988A4 (en) | ANTI-GAP43 ANTIBODY | |
EP2714074A4 (en) | ANTIBODIES AGAINST EMR1 | |
EP2811018A4 (en) | ANTI-BODY ANTI-sAPPß | |
GB201116342D0 (en) | Antigen combinations |